Key facts
- This page summarizes Peter Libby's Form 4 filing for XBiotech Inc. (XBIT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Jun 2022, 17:54.
Peter Libby - 22 Jun 2022 Form 4 Insider Report for XBiotech Inc. (XBIT)
- Reporting relationship
- Director
- Issuer ticker
- XBIT
- Reported as of
- 22 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jun 2022, 17:54:18 UTC
- Prior SEC filing
- 12 Jul 2021
- Next SEC filing
- 26 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /S/ Queena Han under Power of Attorney for Peter Libby
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter Libby filed Form 4 for XBiotech Inc. (XBIT) on 27 Jun 2022.
Change
- Previous filing in this sequence was filed on 12 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XBIT
transaction
Derivative
Director Stock option
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 22 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $5.89
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
On June 22, 2022 (the Grant Date) the reporting person was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions at six month and one year from the Grant Date with an expiry of ten years from the Grant Date.